Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial
Prostate Cancer Prostatic Dis. 2022 Sep;25(3):597.
doi: 10.1038/s41391-021-00477-3.
1 Department of Urology, Vanderbilt University Medical Center, Nashville, TN, USA. david.penson@vumc.org.
2 Division of Medical Oncology, Department of Medicine, Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC, USA.
3 The Comprehensive Prostate Center, Nashville, TN, USA.
4 Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
5 Accumed Research Associates, Garden City, NY, USA.
6 The Urology Center of Colorado, Denver, CO, USA.
7 Urological Associates of Southern Arizona, Tucson, AZ, USA.
8 Global Product Development, Pfizer Inc., Groton, CT, USA.
9 Global Product Development, Pfizer Inc., Collegeville, PA, USA.
10 Biostatistics, Astellas Pharma, Inc., Northbrook, IL, USA.
11 Global Development, Astellas Pharma, Inc., Northbrook, IL, USA.
12 Department of Medicine, Division of Oncology, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, USA.